▎药明康德内容团队编辑 《柳叶刀》:Tirzepatide单药治疗2型糖尿病,显著改善血糖和体重 截图来源:The Lancet
NEJM:Tirzepatide降糖和减重效果优于现有GLP-1受体激动剂 截图来源:The New England Journal of Medicine
参考资料(可上下滑动查看) [1] Julio Rosenstock, et al., (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, DOI: [2] Tricia M-M Tan, Bernard Khoo. (2021). Tirzepatide and the new era of twincretins for diabetes. The Lancet, DOI: https:///10.1016/S0140-6736(21)01390-8 [3] Juan P. Frías, et al., (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The N Engl J Med, DOI: 10.1056/NEJMoa2107519 [4] Katherine R. Tuttle. (2021). Breaking New Ground with Incretin Therapy in Diabetes. The N Engl J Med, DOI: 10.1056/NEJMe2109957 [5] Lilly, Novo Nordisk Present Promising Data in Type 2 Diabetes. Retrieved June 29, 2021, from https://www./article/eli-lilly-novo-nordisk-present-promising-data-for-type-2-diabetes-patients/ [6] Combo GIP/GLP-1 Drug Superior for HbA1c Reduction in T2D. Retrieved June 28, 2021, from https://www./meetingcoverage/ada/93288 [7] Peters on Tirzepatide: 'Impressive, but We Need to Know More'. Retrieved June 28, 2021, from https://www./viewarticle/953053 注:本文旨在介绍医药健康研究进展,不是治疗方案推荐。如需获得治疗方案指导,请前往正规医院就诊。 |
|